10/19/2005 5:12:38 PM
SAN DIEGO--(BUSINESS WIRE)--Feb. 7, 2005--Takeda Pharmaceutical Company Limited (Osaka, Japan, "Takeda," president and chief operating officer: Yasuchika Hasegawa) announced today that Takeda and Syrrx Inc. (San Diego, CA, "Syrrx," chairman of the board: Samuel D. Colella) agreed on February 5, 2005 (PST) to merge Syrrx, Inc. into the Takeda Group. The merger is subject to clearance under the Hart-Scott-Rodino Antitrust Improvements Act and is subject to the satisfaction of other customary closing conditions. Upon successful completion of the transaction, which is anticipated to occur in the first quarter of 2005, Syrrx will become a subsidiary of Takeda America Holdings, Inc., a wholly owned subsidiary of Takeda.
comments powered by